123 related articles for article (PubMed ID: 6974776)
1. Pharmacological and therapeutic properties of carrier bound methotrexate against tumor confined to a third space body compartment.
Chu BC; Howell SB
J Pharmacol Exp Ther; 1981 Nov; 219(2):389-93. PubMed ID: 6974776
[TBL] [Abstract][Full Text] [Related]
2. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
Chu BC; Fan CC; Howell SB
J Natl Cancer Inst; 1981 Jan; 66(1):121-4. PubMed ID: 6935452
[TBL] [Abstract][Full Text] [Related]
3. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
[TBL] [Abstract][Full Text] [Related]
4. Control of solid tumor metastases with a high-molecular-weight derivative of methotrexate.
Chu BC; Whiteley JM
J Natl Cancer Inst; 1979 Jan; 62(1):79-82. PubMed ID: 281578
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
6. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
Samuels LL; Straw JA
Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
[TBL] [Abstract][Full Text] [Related]
8. Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.
Bender RA; Nichols AP; Norton L; Simon RM
Cancer Treat Rep; 1978 Jul; 62(7):997-1003. PubMed ID: 688252
[TBL] [Abstract][Full Text] [Related]
9. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
[TBL] [Abstract][Full Text] [Related]
11. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.
Bures L; Bostík J; Motycka K; Spundová M; Rehák L
Neoplasma; 1988; 35(3):329-42. PubMed ID: 3405341
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
13. Reversal of methotrexate inhibition of colony growth of L1210 leukemia cells in semisolid medium.
Nederbragt H; Uitendaal MP; van der Grint L; Leyva A; Pinedo HM
Cancer Res; 1981 Mar; 41(3):1193-8. PubMed ID: 6970074
[TBL] [Abstract][Full Text] [Related]
14. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
15. Localized chemotherapy of Gardner's lymphosarcoma of C3H mice using combinations of carrier-sorbed antifolics and detoxicating tetrahydrofolates.
Motycka K; Slavík K; Balcarová A; Spacek P; Kubín M
Czech Med; 1981; 4(1-2):14-24. PubMed ID: 6973453
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of methotrexate toxicity by dipyridamole.
Nelson JA; Drake S
Cancer Res; 1984 Jun; 44(6):2493-6. PubMed ID: 6586287
[TBL] [Abstract][Full Text] [Related]
17. l-5-formyltetrahydrofolate and l-5-methyltetrahydrofolate rescue in L1210 leukemia treated with high methotrexate doses.
Simile MM; DeMiglio MR; Nufris A; Pascale RM; Muroni MR; Feo F
Res Commun Chem Pathol Pharmacol; 1993 Aug; 81(2):251-4. PubMed ID: 8210704
[TBL] [Abstract][Full Text] [Related]
18. Characterization of in-vitro drug release and biological activity of methotrexate-bovine serum albumin conjugates.
Halbert GW; Florence AT; Stuart JF
J Pharm Pharmacol; 1987 Nov; 39(11):871-6. PubMed ID: 2892908
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of methotrexate--with emphasis on use of high doses.
Bertino JR
Cancer Treat Rep; 1981; 65 Suppl 1():131-5. PubMed ID: 6976829
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral administration of methotrexate bound to activated carbon particles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice.
Nakase Y; Hagiwara A; Kin S; Fukuda K; Ito T; Takagi T; Fujiyama J; Sakakura C; Otsuji E; Yamagishi H
J Pharmacol Exp Ther; 2004 Oct; 311(1):382-7. PubMed ID: 15175420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
